A Clinical Practice‐Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70039 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Anthony Damiani und 27 weiteren Autor:innen. Beteiligte Einrichtung: SA Pharmacy, Central Adelaide Local Health Network, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Enoxaparin, Anticoagulants, Factor Xa Inhibitors. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South Australian Association of Internal Medicine.
Abstract (Originalsprache)
To understand differences in anti‐factor‐Xa levels produced by two different dosing strategies (conventional and individualized) for therapeutic enoxaparin in a cohort of hospital inpatients. A multicenter, retrospective cohort study over a two‐ and a half‐year period for inpatients with stable renal function and on therapeutic enoxaparin. Anti‐factor‐Xa levels were taken 3–5 h after enoxaparin administration and a minimum of 48 h of dosing. The final analysis included 278 patients from five hospitals: conventional dosing was used for 141, while 137 were given an unconventional dose, that is, individualized for their renal function and weight. Out‐of‐range levels were frequent (35% to 40% of all inpatients). After adjustment for age, renal function, and body mass index (BMI), the conventional group was more likely to experience above‐range levels (> 1.0 IU/mL; OR 2.50 [95% CI 1.38–4.56], p < 0.003) than the individualized group. Individualized dosing was independently associated with higher odds of a below‐range anti‐Xa level (< 0.5 IU/mL) compared to conventional dosing (OR 2.27 [95% CI 1.07–4.76], p = 0.03). Within the conventional group, above‐range levels were significantly and independently associated with decreasing renal function (OR 0.97, 95% CI 0.96–0.99, p = 0.004) and with increasing BMI (OR 1.06, 95% CI 1.01–1.10, p = 0.02). No such associations were seen with an individualized approach. Clinical event rates were low and not different between groups ( p > 0.24). Conventional therapeutic dosing of enoxaparin exposed people with obesity or renal impairment to more frequent above‐range anti‐factor‐Xa levels; individualizing the dose could improve this but might expose people to subtherapeutic levels. More research is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SA Pharmacy, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
- School of Allied Health Science and Practice, The University of Adelaide, Adelaide, South Australia, Australia.
- SA Pharmacy, Southern Adelaide Local Health Network, Adelaide, South Australia, Australia.
- Pharmacy and Biomedical Sciences, University of South Australia, Adelaide, South Australia, Australia.
- Department of Internal Medicine, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
- Medical Services Division, Northern Adelaide Local Health Network, Adelaide, South Australia, Australia.
ORCID-Profile: Viviane De Menezes Caceres, Arduino A Mangoni, Patrick Russell
Förderung
- South Australian Association of Internal Medicine
Zitieren
APA
Damiani, A., De Menezes Caceres, V., Roberts, G., Coddo, J., Scarfo, N., Willliams, D. B., Tharmathurai, V., Tadros, R., Fitzgerald, S., O'Connell, A., Kaur Sandhu, A., Vanlint, A., Mangoni, A. A., Hofmann, D., Bony, H., Faunt, J., Boey, J. P., Farinola, N., Wells, R., …, & Russell, P. (2025). A Clinical Practice‐Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70039
Vancouver
Damiani A, De Menezes Caceres V, Roberts G, Coddo J, Scarfo N, Willliams DB, et al. A Clinical Practice‐Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70039
BibTeX
@article{Damiani2025,
author = {Damiani, Anthony and De Menezes Caceres, Viviane and Roberts, Greg and Coddo, Jessica and Scarfo, Nicholas and Willliams, Desmond B and Tharmathurai, Vinosshini and Tadros, Rami and Fitzgerald, Stephen and O'Connell, Alice and Kaur Sandhu, Amrit and Vanlint, Andrew and Mangoni, Arduino A and Hofmann, Dirk and Bony, Hosam and Faunt, Jeff and Boey, Jir Ping and Farinola, Nicholas and Wells, Rachel and Hedger, Stephen and Hewage, Udul and Sharma, Yogesh and Jabbar, Zuhair and Thomas, Josephine and Flabouris, Katerina and Gilbert, Toby and Thompson, Campbell and Russell, Patrick},
title = {A Clinical Practice‐Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70039}
}
EUVIMED